fulvestrant has been researched along with fluorodeoxyglucose f18 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, KE; Chan, SR; Dence, CS; Fettig, NM; Fowler, AM; Jeyakumar, M; Katzenellenbogen, JA; Schreiber, RD; Sharp, TL; Welch, MJ; Zhou, D | 1 |
| Currin, ER; Krohn, KA; Kurland, BF; Lee, JH; Linden, HM; Link, JM; Mankoff, DA; Peterson, LM; Schubert, EK | 1 |
| Gong, C; Li, Y; Liu, C; Wang, B; Wu, B; Xie, Y; Yang, Z; Zhang, Y; Zhao, Y | 1 |
| Di, G; He, M; Liu, C; Liu, G; Liu, Y; Shao, Z; Shi, Q; Sun, Y; Wang, Z; Xu, X; Yang, Z; Yuan, H; Zhang, Y | 1 |
1 trial(s) available for fulvestrant and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
Topics: Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2018 |
3 other study(ies) available for fulvestrant and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Neoplasm Transplantation; Norpregnenes; Positron-Emission Tomography; Predictive Value of Tests; Rabbits; Radiopharmaceuticals; Receptors, Steroid; STAT1 Transcription Factor | 2012 |
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2 | 2017 |
The Predictive Value of Early Changes in
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Estrogen | 2020 |